Incyte Corporation (INCY)

[surf1944]

8:05AM Incyte announces data from 3 phase II trials to be presented at the ASH annual meeting demonstrate that INCB18424, has potential in multiple hematology conditions (INCY) 8.29 +0.22 : Co announces that INCB18424 its selective, orally available janus kinase inhibitor, will be the subject of three oral presentations at the 51st American Society of Hematology Annual Meeting in New Orleans. "INCB18424 continues to provide durable and previously unachievable clinical benefits in patients with myelofibrosis with or without JAK2 activating mutations. It is equally gratifying to see significant clinical benefits in patients with advanced polycythemia vera and essential thrombocythemia including normalization of blood counts, normalization of hematocrit without the need for phlebotomy, rapid and durable reductions in enlarged spleens as well as rapid and durable reductions in symptoms, particularly pruritus. "Additionally, in an exploratory trial in highly refractory patients with secondary acute myeloid leukemia and other leukemias for which no standard therapies are likely to lead to a durable remission, it is encouraging to see patients obtain clinical benefit including the achievement of stable disease as well as complete and partial responses. Our experience with INCB18424 in these highly refractory leukemia patients, along with the growing body of evidence indicating that JAK activation may play a determining role in a number of hematologic malignancies, suggests that use of a selective JAK inhibitor may help provide underserved patients in multiple hematological cancers with improved clinical outcomes."